Pharmaceutical compositions and dosage forms of thalidomide
AssigneeCelgene Corporation
InventorsPaul D'Angio, John McCarty
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable stereoisomers, prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating, managing, and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
Claims20
A single unit dosage form in the form of a size 1 capsule comprising 150 mg of thalidomide and 223.1 mg of a carrier.
A single unit dosage form in the form of a size 4 capsule comprising 25 mg of thalidomide and 99.4 mg of a carrier.
Dependencies are inferred from the claim text.